Articles from Biora Therapeutics, Inc.

Emerges as a privately held company, with long-term financing to accelerate development of the BioJet™ platform

Sale process will help enable next stage of product development

Testing in advanced animal model planned in Q4 for smaller, 00-size BioJet device with largest capacity of any ingestible injectable

SAN DIEGO, Nov. 07, 2024 (GLOBE NEWSWIRE) -- Biora Therapeutics, Inc. (Nasdaq: BIOR), the biotech company reimagining therapeutic delivery, today announced it will report financial results and provide a corporate update for the third quarter ended September 30, 2024. Company management will host a webcast and conference call on Thursday, November 14, 2024, after the close of financial markets.

SAN DIEGO, Oct. 29, 2024 (GLOBE NEWSWIRE) -- Biora Therapeutics, Inc. (Nasdaq: BIOR), the biotech company reimagining therapeutic delivery, today announced that it has entered into definitive agreements for the purchase and sale of 745,342 shares of the Company’s common stock at an offering price of $4.025 per share of common stock in a registered direct offering priced at-the-market under Nasdaq rules. In addition, in a concurrent private placement, the Company will issue unregistered warrants to purchase up to 745,342 shares of common stock. The warrants have an exercise price of $3.90 per share, will be exercisable upon issuance, and will expire five years following issuance. The closing of the offering is expected to occur on or about October 29, 2024, subject to the satisfaction of customary closing conditions.

Expanded collaborations to support rapid testing in advanced animal models in Q4 2024

SAN DIEGO, Oct. 14, 2024 (GLOBE NEWSWIRE) -- Biora Therapeutics, Inc. (Nasdaq: BIOR), the biotech company reimagining therapeutic delivery, today announced that Adi Mohanty, CEO of Biora Therapeutics, will present on the company’s 00-size BioJet™ device at the 14th Annual Partnership Opportunities in Drug Delivery (PODD) meeting, taking place in Boston, October 28–29, 2024.

SAN DIEGO, Oct. 07, 2024 (GLOBE NEWSWIRE) -- Biora Therapeutics, Inc. (Nasdaq: BIOR), the biotech company reimagining therapeutic delivery, today announced that company leadership will present at the 19th Annual Peptide Therapeutics Symposium, taking place virtually and in person in La Jolla, California, October 22–23, 2024. Details of the presentation are as follows:

SAN DIEGO, Sept. 30, 2024 (GLOBE NEWSWIRE) -- Biora Therapeutics, Inc. (Nasdaq: BIOR), the biotech company reimagining therapeutic delivery, today announced an upcoming poster presentation at the American College of Gastroenterology (ACG) Annual Scientific Meeting, which will be held in Philadelphia, October 25–30, 2024.

Underscoring the company’s commitment to quality and excellence

Company granted extension to regain compliance with Nasdaq listing requirements

SAN DIEGO, Aug. 26, 2024 (GLOBE NEWSWIRE) -- Biora Therapeutics, Inc. (Nasdaq: BIOR), the biotech company reimagining therapeutic delivery, today announced that company leadership will participate in the H.C. Wainwright 26th Annual Global Investment Conference, September 9–11, 2024.

Phase 1 clinical trial results for BT-600 demonstrate precise drug delivery to the colon with low systemic exposure, supporting clinical development plan

$16 million multiple-draw facility to be used as a bridge to anticipated pharma partnership

SAN DIEGO, Aug. 08, 2024 (GLOBE NEWSWIRE) -- Biora Therapeutics, Inc. (Nasdaq: BIOR), the biotech company reimagining therapeutic delivery, today announced it will report financial results and provide a corporate update for the second quarter ended June 30, 2024. Company management will host a webcast and conference call on Monday, August 12, 2024, after the close of financial markets.

SAN DIEGO, Aug. 06, 2024 (GLOBE NEWSWIRE) -- Biora Therapeutics, Inc. (Nasdaq: BIOR), the biotech company reimagining therapeutic delivery, today announced that company leadership will participate in the Canaccord Genuity 44th Annual Growth Conference, August 13–15, 2024.

Pharmacokinetic and tissue data confirm NaviCap platform delivers topically through the entire colon, with lower systemic concentrations, as desired

SAN DIEGO, July 08, 2024 (GLOBE NEWSWIRE) -- Biora Therapeutics, Inc. (Nasdaq: BIOR), the biotech company reimagining therapeutic delivery, today announced further details on its virtual event to be held on Wednesday, July 17, 2024. The event will feature Bruce Sands, MD, MS (Icahn School of Medicine at Mount Sinai) and Brian Feagan, MD, FRCPC (Schulich School of Medicine & Dentistry at the University of Western Ontario), who will discuss the unmet need and current treatment landscape for patients with ulcerative colitis (UC), as well as the value of colonic drug delivery for improving efficacy.

Drug-device combination leverages Biora’s NaviCap™ platform to deliver tofacitinib directly to colonic tissue as a potential treatment for ulcerative colitis

SAN DIEGO, June 11, 2024 (GLOBE NEWSWIRE) -- Biora Therapeutics, Inc. (Nasdaq: BIOR), the biotech company that is reimagining therapeutic delivery, today announced that it will present preclinical data from the BioJet™ Systemic Oral Delivery Platform at the Next Gen Peptide Formulation & Delivery Summit, which will take place June 18–20, 2024 in Boston.

Four clinical device performance studies successfully demonstrate the NaviCap platform’s ability to deliver therapeutics directly to the colon under variable GI conditions and eating schedules

Dosing of all patients in clinical trial of BT-600 has been successfully completed, with results anticipated in late Q2 2024

SAN DIEGO, May 07, 2024 (GLOBE NEWSWIRE) -- Biora Therapeutics, Inc. (Nasdaq: BIOR), the biotech company that is reimagining therapeutic delivery, today announced it will report financial results and provide a corporate update for the first quarter ended March 31, 2024. The company’s management will host a webcast and conference call on Wednesday, May 15, 2024, after the close of financial markets.

SAN DIEGO, May 06, 2024 (GLOBE NEWSWIRE) -- Biora Therapeutics, Inc. (Nasdaq: BIOR), the biotech company that is reimagining therapeutic delivery, today announced that it will present clinical data on device function of the NaviCap™ Targeted Oral Delivery Platform at Digestive Disease Week® (DDW), which will take place both virtually and in-person May 18-21, 2024 in Washington, DC.

Dosing of all patients in the trial has been successfully completed

Claims cover key jet parameters for liquid jet delivery of a drug to the gastrointestinal tract

All pharmacokinetic endpoints were achieved, with a PK profile consistent with drug delivery and absorption in the colon

SAN DIEGO, April 03, 2024 (GLOBE NEWSWIRE) -- Biora Therapeutics, Inc. (Nasdaq: BIOR), the biotech company that is reimagining therapeutic delivery, today announced the closing of its previously announced registered direct offering of an aggregate of 5,454,548 shares of the Company’s common stock at an offering price of $1.10 per share of common stock and concurrent private placement of unregistered warrants to purchase up to 5,454,548 shares of common stock. The warrants have an exercise price of $1.10 per share, will be exercisable beginning on the effective date of stockholder approval of the issuance of the shares issuable upon exercise of the warrants, and will expire five years from the date of stockholder approval.

SAN DIEGO, April 01, 2024 (GLOBE NEWSWIRE) -- Biora Therapeutics, Inc. (Nasdaq: BIOR), the biotech company that is reimagining therapeutic delivery, today announced that it has entered into definitive agreements for the purchase and sale of 5,454,548 shares of the Company’s common stock at an offering price of $1.10 per share of common stock in a registered direct offering priced at-the-market under Nasdaq rules. In addition, in a concurrent private placement, the Company will issue unregistered warrants to purchase up to 5,454,548 shares of common stock. The warrants have an exercise price of $1.10 per share, will be exercisable beginning on the effective date of stockholder approval of the issuance of the shares issuable upon exercise of the warrants, and will expire five years from the date of stockholder approval. The closing of the offering is expected to occur on or about April 3, 2024, subject to the satisfaction of customary closing conditions.

All performance targets achieved in single-ascending dose (SAD) cohorts of BT-600 clinical trial

SAN DIEGO, March 18, 2024 (GLOBE NEWSWIRE) -- Biora Therapeutics, Inc. (Nasdaq: BIOR), the biotech company that is reimagining therapeutic delivery, today announced it will report financial results and provide a corporate update for the fourth quarter and full year ended December 31, 2023. The company’s management will host a webcast and conference call on Tuesday, March 26, 2024, after the close of financial markets.

Monetization of legacy asset brings in $3 million in nondilutive capital

Data expected to be shared during March corporate update

SAN DIEGO, Feb. 08, 2024 (GLOBE NEWSWIRE) -- Biora Therapeutics, Inc. (Nasdaq: BIOR), the biotech company that is reimagining therapeutic delivery, today announced it will participate in the Inflammatory Bowel Disease Symposium hosted virtually by Canaccord Genuity Capital Markets on Wednesday, February 28, 2024.

SAN DIEGO, Jan. 22, 2024 (GLOBE NEWSWIRE) -- Biora Therapeutics, Inc. (Nasdaq: BIOR), the biotech company that is reimagining therapeutic delivery, today announced participation in a virtual fireside chat hosted by H.C. Wainwright & Co. on Monday, January 29, 2024 at 11:00 AM Eastern / 8:00 AM Pacific.

Multiple catalysts anticipated in 2024, including clinical study results for NaviCap™ Targeted Oral Delivery Platform and progress on pharma partnerships for BioJet™ Systemic Oral Delivery Platform

First-in-human trial of BT-600 drug-device combination, following multiple successful device-only human studies

BioJet device exceeded performance targets for delivery of collaborator AstraZeneca’s molecule in preclinical study

Patent addresses targeted delivery of JAK inhibitors to the gastrointestinal tract

Transaction results in nearly 60% reduction in net debt and brings $16.7 million in new capital for the company

Pharma collaborator’s proprietary molecules will be tested with the BioJet platform in animal models

BT-600 will deliver a proprietary liquid formulation of tofacitinib via the NaviCap™ device for topical delivery to the colon

NaviCap™ Targeted Oral Delivery platform advancing toward initiation of phase 1 clinical trial by year end

SAN DIEGO, Nov. 06, 2023 (GLOBE NEWSWIRE) -- Biora Therapeutics, Inc. (Nasdaq: BIOR), the biotech company that is reimagining therapeutic delivery, today announced it will report financial results and provide a corporate update for the third quarter ended September 30, 2023.   The company’s management will host a webcast and conference call on Monday, November 13, 2023, after the close of financial markets at 4:30 PM Eastern time / 1:30 PM Pacific time.

Update includes supplemental information and provides additional time to complete regulatory review

Biora anticipates remaining on track with its phase 1 clinical trial execution timeline

Autonomous next-gen device exceeded performance targets in three recent preclinical studies

BT-600 is a drug/device combination delivering a liquid formulation of tofacitinib via the NaviCap™ platform for the treatment of ulcerative colitis

Funds managed by Athyrium Capital Management increase their equity exposure through a convertible notes exchange at a price representing a 44% premium to the closing price on September 18, 2023

SAN DIEGO, Sept. 11, 2023 (GLOBE NEWSWIRE) -- Biora Therapeutics, Inc. (Nasdaq: BIOR), the biotech company that is reimagining therapeutic delivery, today announced it will present at the upcoming H.C. Wainwright 25th Annual Global Investment Conference being held September 11-13, 2023 in New York City.

Confirmation of autonomous device function enables progress to testing of pharma collaborators’ molecules

NaviCap™ targeted oral delivery platform on track for September IND filing; achieved successful device function study results in humans with phase 1-ready device

Intellectual property relates to key features of the company’s liquid jet injection technology

SAN DIEGO, Aug. 02, 2023 (GLOBE NEWSWIRE) -- Biora Therapeutics, Inc. (Nasdaq: BIOR), the biotech company that is reimagining therapeutic delivery, today announced that management will be attending the Canaccord Genuity 43rd Annual Growth Conference in Boston.

Phase 1-ready device shows 100% success in human functional study of twelve subjects to date

SAN DIEGO, July 17, 2023 (GLOBE NEWSWIRE) -- Biora Therapeutics, Inc. (Nasdaq: BIOR), the biotech company that is reimagining therapeutic delivery, today announced that it will report financial results and provide a corporate update for the second quarter ended June 30, 2023. The company’s management will host a webcast and conference call on Monday, August 14, 2023, after the close of financial markets at 4:30 PM Eastern time / 1:30 PM Pacific time.

SAN DIEGO, July 05, 2023 (GLOBE NEWSWIRE) -- Biora Therapeutics, Inc. (Nasdaq: BIOR), the biotech company that is reimagining therapeutic delivery, today announced that it has completed an agreement with a large diagnostics company for the sale of legacy assets related to Biora’s former diagnostics business.

SAN DIEGO, June 28, 2023 (GLOBE NEWSWIRE) -- Biora Therapeutics, Inc. (Nasdaq: BIOR), the biotech company that is reimagining therapeutic delivery, today announced that it has been awarded a group of US and European patents related to several additional therapeutic targets for its NaviCap™ targeted oral delivery platform under development.

An average bioavailability of 37% for a GLP-1 receptor agonist was achieved in animals

SAN DIEGO, June 13, 2023 (GLOBE NEWSWIRE) -- Biora Therapeutics, Inc. (Nasdaq: BIOR), the biotech company that is reimagining therapeutic delivery (“Biora” or the “Company”), today announced that it has entered into a definitive agreement for the purchase and sale of 1,509,434 shares of the Company’s common stock at an offering price of $5.30 per share of common stock in a registered direct offering priced at-the-market under Nasdaq rules. In addition, in a concurrent private placement, the Company will issue unregistered warrants to purchase up to 3,018,868 shares of common stock. The warrants have an exercise price of $5.05 per share, will be exercisable upon issuance, and will expire three years following issuance. The closing of the offering is expected to occur on or about June 14, 2023, subject to the satisfaction of customary closing conditions.

SAN DIEGO, June 08, 2023 (GLOBE NEWSWIRE) -- Biora Therapeutics, Inc. (Nasdaq: BIOR), the biotech company that is reimagining therapeutic delivery, today announced that it will present preclinical data on oral delivery of a GLP-1 receptor agonist with its BioJet systemic oral delivery platform in a short oral discussion at the 59th annual meeting of the European Association for the Study of Diabetes, to be held October 2–6, 2023 in Hamburg, Germany.

Completed execution of toxicology study for NaviCap™ BT-600 program with no adverse events indicated in preliminary data; on track to file IND in Q3 2023

SAN DIEGO, May 08, 2023 (GLOBE NEWSWIRE) -- Biora Therapeutics, Inc. (Nasdaq: BIOR), the biotech company that is reimagining therapeutic delivery, today announced that it will report first quarter ended March 31, 2023 financial results on Monday, May 15, 2023 after the close of financial markets. The company’s management will host a webcast and conference call at 4:30 PM Eastern time / 1:30 PM Pacific time that day to discuss the financial results and provide a corporate update.

SAN DIEGO, May 01, 2023 (GLOBE NEWSWIRE) -- Biora Therapeutics, Inc. (Nasdaq: BIOR), the biotech company that is reimagining therapeutic delivery, today announced the appointment of Ariella Kelman, MD, as Chief Medical Officer. Dr. Kelman has a proven track record of leading global biopharmaceutical development, clinical trials, and regulatory strategies.

SAN DIEGO, April 20, 2023 (GLOBE NEWSWIRE) -- Biora Therapeutics, Inc. (Nasdaq: BIOR), the biotech company that is reimagining therapeutic delivery, today announced that it will participate in IBD Innovate: Product Development for Crohn’s & Colitis, an event hosted by the Crohn’s & Colitis Foundation to showcase innovative product development programs in inflammatory bowel disease (IBD), which will take place in New York City on April 26, 2023.

Biora initiating preclinical testing with pharma collaborator’s molecule following recent data exceeding the company’s target bioavailability levels for systemic therapeutics platform

SAN DIEGO, March 23, 2023 (GLOBE NEWSWIRE) -- Biora Therapeutics, Inc. (Nasdaq: BIOR), the biotech company that is reimagining therapeutic delivery, today announced that it will report fourth quarter and full year ended December 31, 2022 financial results on Thursday, March 30, 2023 after the close of financial markets. The company’s management will host a webcast and conference call at 4:30 PM Eastern time / 1:30 PM Pacific time that day to discuss the financial results and provide a corporate update.

Preclinical data demonstrate potential to orally deliver peptides and monoclonal antibodies at bioavailability levels more than double the company’s current target

Average bioavailability greater than 50% with high consistency observed in animal study

Study demonstrates targeted delivery devices functioned as designed when administered with food, potentially enabling non-fasted administration

Company is on track to move into the clinic with its lead targeted therapeutics program

SAN DIEGO, Dec. 30, 2022 (GLOBE NEWSWIRE) -- Biora Therapeutics, Inc. (Nasdaq: BIOR), the biotech company that is reimagining therapeutic delivery, today announced it will effect a reverse stock split of all outstanding shares of the company’s common stock at a ratio of 25 to 1. The company expects its common stock to begin trading on a split-adjusted basis on the Nasdaq Global Market as of the commencement of trading on January 3, 2023.

SAN DIEGO, Dec. 08, 2022 (GLOBE NEWSWIRE) -- Biora Therapeutics, Inc. (Nasdaq: BIOR), the biotech company that is reimagining therapeutic delivery, today announced acceptance of two abstracts presenting patient data on its targeted therapeutics delivery system for presentation at the Crohn’s & Colitis Congress, which will take place January 19-21, 2023, in Denver, Colorado. This annual conference, a partnership of the Crohn’s & Colitis Foundation and the American Gastroenterological Association, is focused on bringing together a multidisciplinary community of health care practitioners and researchers to transform inflammatory bowel disease care.

Avero Diagnostics to Develop and Commercialize, Enabling Potential Future Revenue for Biora Therapeutics

Presented results of human study at the American College of Gastroenterology annual meeting, demonstrating promising device performance in active ulcerative colitis patients